Last Updated on July 24, 2024 by The Health Master
Clinical Trial
In a move with significant implications for patients suffering from constipation, the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has granted permission to BDR Pharmaceuticals to conduct a Phase III clinical trial of their new Linaclotide Capsules (290 mcg).
This decision comes after BDR Pharmaceuticals presented a proposal requesting permission to manufacture and market the drug, along with justification for both a bioequivalence (BE) waiver and a Phase III clinical trial waiver.
What is Linaclotide?
Linaclotide is a medication belonging to a class of drugs known as guanylate cyclase-C (GC-C) agonists.
It works by targeting a specific enzyme in the intestinal lining, promoting fluid secretion and accelerating the passage of stool through the gut.
This mechanism offers relief from various constipation-related conditions, including:
- Irritable Bowel Syndrome with Constipation (IBS-C)
- Idiopathic Constipation (chronic constipation with no underlying cause)
- Functional Constipation (constipation due to problems with the muscles or nerves in the gut)
Linaclotide’s Unique Mechanism of Action
Linaclotide boasts a two-pronged approach to treating constipation:
Increased Intestinal Fluid and Motility:
Linaclotide binds to GC-C receptors, leading to a rise in cGMP levels within intestinal cells.
This activates specific channels responsible for secreting chloride and bicarbonate ions, while simultaneously inhibiting sodium absorption.
The resulting increase in intestinal fluid content promotes smoother and faster stool passage.
Reduced Pain Perception:
Linaclotide also exerts pain-relieving effects by lowering visceral hypersensitivity.
By elevating cGMP levels in the gut lining, it dampens the activity of colonic pain receptors, offering relief from intestinal discomfort commonly associated with constipation.
The SEC’s Decision and Next Steps
During a recent SEC meeting dedicated to gastroenterology and hepatology (June 20, 2024), the committee reviewed BDR Pharmaceuticals’ proposal for Linaclotide capsules.
After careful evaluation, the committee acknowledged that another applicant had previously received approval for a Phase III trial with a BE waiver for a similar Linaclotide formulation.
Based on this precedent, the SEC granted BDR Pharmaceuticals a BE waiver, eliminating the need for a separate study to demonstrate their capsules are equivalent to existing Linaclotide products in terms of absorption and delivery.
However, the committee recommended against waiving the Phase III clinical trial.
This means BDR Pharmaceuticals will need to conduct a full-scale Phase III trial to assess the drug’s safety and efficacy in a larger patient population.
The SEC advised the company to submit a detailed Phase III clinical protocol for further consideration.
Looking Ahead
BDR Pharmaceuticals’ successful application for a Phase III trial marks a significant step forward in the development of Linaclotide capsules as a potential treatment option for constipation.
With the completion of the clinical trial, this new medication could offer much-needed relief to millions of patients struggling with this condition.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
CDSCO Panel approval granted for Clinical Trial of this Anti Cancer Drug
Specific Regulations required for New Drugs and Clinical Trial Rules for Homoeopathy
CDSCO releases draft Guidelines for Clinical Trial in India
Understanding the CDSCO’s Decision on Clinical Trial Waiver
CDSCO approval granted for Clinical Trials of XBB.1.5 Vaccine
Budget 2024: Mixed Bag for Indian Pharma Industry
Drug alert: 61 drug samples declared as NSQ in June 2024
Fire breaks out at Pharma Plant in Maharashtra
Drug recall: Sanofi recalls Allegra, Combiflam suspensions due to this reason
Simple Urine Test a Lifesaver: Especially for Diabetics and High BP
Zydus receives favorable outcome After USFDA Inspection
USFDA approval granted for Topiramate Capsules USP
USFDA declines to approve this Nasal Spray
USFDA inspection concluded at Divi’s Labs with one observation
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
